The role of serum biomarkers in predicting fibrosis progression in pediatric and adult hepatitis C virus chronic infection

PLoS ONE

Volumn 6, Issue 8, 2011, Pages

  Valva, Pamela ^a   Casciato, Paola ^b   Carrasco, Juan M Diaz ^a   Gadano, Adrian ^b   Galdame, Omar ^b   Galoppo, María Cristina ^a   Mullen, Eduardo ^b   de Matteo, Elena ^a   Preciado, María Victoria ^a  

^a HOSPITAL DE NIÑOS RICARDO GUTIÉRREZ   (Argentina)

^b HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; HYALURONIC ACID; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA1; PEPTIDE FRAGMENT; PROCOLLAGEN; PROCOLLAGEN TYPE III N TERMINAL PEPTIDE; PROCOLLAGEN TYPE III-N-TERMINAL PEPTIDE;

ADOLESCENT; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CHILD; CHRONIC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FATTY LIVER; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; LYMPH FOLLICLE; MALE; PREDICTION; PRESCHOOL CHILD; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; RISK FACTOR; SCHOOL CHILD; SMOKING; VIRUS LOAD; BIOPSY; BLOOD; IMMUNOASSAY; INFANT; LIVER; LIVER CIRRHOSIS; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PREDICTIVE VALUE; VIROLOGY;

HEPATITIS C VIRUS;

ADOLESCENT; ADULT; AGED; BIOLOGICAL MARKERS; BIOPSY; CHILD; CHILD, PRESCHOOL; DISEASE PROGRESSION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; HYALURONIC ACID; IMMUNOASSAY; INFANT; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PROCOLLAGEN; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TRANSFORMING GROWTH FACTOR BETA1;

EID: 80051712424     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0023218     Document Type: Article

References (60)

1. Murray K, Finn L, Taylor S, Seidel K, Larson A, (2005) Liver histology and alanine aminotransferase levels in children and adults with chronic hepatitis C infection. J Pediatr Gastroenterol Nutr 41: 634-638.
2. Kage M, Fujisawa T, Shiraki K, Tanaka T, Fujisawa T, et al. (1997) Pathology of chronic hepatitis C in children. Child Liver Study Group of Japan. Hepatology 26: 771-775.
3. Badizadegan K, Jonas M, Ott M, Nelson S, Perez-Atayde A, (1998) Histopathology of the liver in children with chronic hepatitis C viral infection. Hepatology 28: 1416-1423.
4. Jara P, Resti M, Hierro L, Giacchino R, Barbera C, et al. (2003) Chronic hepatitis C virus infection in childhood: clinical patterns and evolution in 224 white children. Clin Infect Dis 36: 275-280.
5. Chen S, Morgan T, (2006) The Natural History of Hepatitis C Virus. Infection Int J Med Sci 3: 47-52.
6. Dienstag J, (2002) The role of liver biopsy in chronic hepatitis. Hepatology 36: S152-160.
7. Bravo A, Sheth S, Chopra S, (2001) Liver biopsy. N Engl J Med 344: 495-500.
8. Thampanitchawong P, Piratvisuth T, (1999) Liver biopsy:complications and risk factors. World J Gastroenterol 5: 301-304.
9. Afdhal N, Nunes D, (2004) Evaluation of liver fibrosis: a concise review. Am J Gastroenterol 99: 1160-1174.
10. Martínez SM, Crespo G, Navasa M, Forns X, (2011) Noninvasive assessment of liver fibrosis. Hepatology 53: 325-335.
11. Manning D, Afdhal N, (2008) Diagnosis and quantitation of fibrosis. Gastroenterology 134: 1670-1681.
12. Gismondi M, Turazza E, Grinstein S, Galoppo M, Preciado M, (2004) Hepatitis C virus infection in infants and children from Argentina. J Clin Microbiol 42: 1199-1202.
13. Sanai F, Benmousa A, Al-Hussaini H, Ashraf S, Alhafi O, et al. (2008) Is serum alanine transaminase level a reliable marker of histological disease in chronic hepatitis C infection? Liver Int 28: 1011-1018.
14. Sebastiani G, Vario A, Guido M, Alberti A, (2008) Performance of noninvasive markers for liver fibrosis is reduced in chronic hepatitis C with normal transaminases. J Viral Hepat 15: 212-218.
15. Pinzani M, Rombouts K, Colagrande S, (2005) Fibrosis in chronic liver diseases: diagnosis and management. J Hepatol 45: S22-36.
16. Saitou Y, Shiraki K, Yamanaka Y, Yamaguchi Y, Kawakita T, et al. (2005) Noninvasive estimation of liver fibrosis and response to interferon therapy by a serum fibrogenesis marker, YKL-40, in patients with HCV-associated liver disease. World J Gastroenterol 28: 476-481.
17. Leroy V, Monier F, Bottari S, Trocme C, Sturm N, et al. (2004) Circulating matrix metalloproteinases 1, 2, 9 and their inhibitors TIMP-1 and TIMP-2 as serum markers of liver fibrosis in patients with chronic hepatitis C: comparison with PIIINP and hyaluronic acid. Am J Gastroenterol 99: 271-279.
18. Sanvisens A, Serra I, Tural C, Tor J, Ojanguren I, et al. (2009) Hyaluronic acid, transforming growth factor-beta1 and hepatic fibrosis in patients with chronic hepatitis C virus and human immunodeficiency virus co-infection. J Viral Hepat 16: 513-518.
19. Fontana R, Goodman Z, Dienstag J, Bonkovsky H, Naishadham D, et al. (2008) Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C. Hepatology 47: 789-798.
20. Martinez S, Fernández-Varo G, González P, Sampson E, Bruguera M, et al. (2011) Assessment of liver fibrosis before and after antiviral therapy by different serum marker panels in patients with chronic hepatitis C. Aliment Pharmacol Ther 33: 138-148.
21. Patel K, Lajoie A, Heaton S, Pianko S, Behling CA, et al. (2003) Clinical use of hyaluronic acid as a predictor of fibrosis change in hepatitis C. J Gastroenterol Hepatol 18: 253-257.
22. Fontana RJ, Bonkovsky HL, Naishadham D, Dienstag JL, Sterling RK, et al. (2009) Serum fibrosis marker levels decrease after successful antiviral treatment in chronic hepatitis C patients with advanced fibrosis. Clin Gastroenterol Hepatol 7: 219-226.
23. Parkes J, Guha IN, Roderick P, Harris S, Cross R, et al. (2011) Enhanced Liver Fibrosis (ELF) test accurately identifies liver fibrosis in patients with chronic hepatitis C. J Viral Hepat 18: 23-31.
24. Macías J, Mira J, Gilabert I, Neukam K, Roldán C, et al. (2011) Combined use of aspartate aminotransferase, platelet count and matrix metalloproteinase 2 measurements to predict liver fibrosis in HIV/hepatitis C virus-coinfected patients. HIV Med 12: 12-21.
25. Moreno S, García-Samaniego J, Moreno A, Ortega E, Pineda J, et al. (2009) Noninvasive diagnosis of liver fibrosis in patients with HIV infection and HCV/HBV co-infection. Viral Hepat 16: 249-258.
26. Forns X, Ampurdanès S, Llovet J, Aponte J, Quintó L, et al. (2002) Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 36: 986-992.
27. Theise N, Bordenheimer H, Ferrel L, (2007) Acute and chronic viral hepatitis. In: Burt AD, Portmann BC, Ferrel LD, editors. MacSweens Pathology of the liver 5° edition cap 8 London Churchill-Livingstone: 418-419.
28. Consenso Argentino de Hepatitis C, (2007) Documento final Consenso Argentino Hepatitis C, Asociación Argentina para el Estudio de las Enfermedades del Hígado.
29. Poynard T, Halfon P, Castera L, Munteanu M, Imbert-Bismut F, et al. (2007) Standardization of ROC curve areas for diagnostic evaluation of liver fibrosis markers based on prevalences of fibrosis stages. Clin Chem 53: 1615-1622.
30. Gebo KA, Herlong HF, Torbenson MS, Jenckes MW, Chander G, et al. (2002) Role of liver biopsy in management of chronic hepatitis C: a systematic review. Hepatology 36: S161-172.
31. Poynard T, Ratziu V, Benhamou Y, Thabut D, J M, (2005) Biomarkers as a first-line estimate of injury in chronic liver diseases: time for a moratorium on liver biopsy? Gastroenterology 128: 1146-1148.
32. Sebastiani G, Alberti A, (2006) Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy. World J Gastroenterol 12: 3682-3694.
33. Castera L, Pinzani M, (2010) Biopsy and non-invasive methods for the diagnosis of liver fibrosis: does it take two to tango? Gut 59: 861-866 2010.
34. Poynard T, Halfon P, Castera L, Charlotte F, Le Bail B, et al. (2007) Variability of the area under the receiver operating characteristic curves in the diagnostic evaluation of liver fibrosis markers: impact of biopsy length and fragmentation. Aliment Pharmacol Ther 25: 733-739.
35. Colloredo G, Guido M, Sonzogni A, Leandro G, (2003) Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J Hepatol 39: 239-244.
36. Regev A, Berho M, Jeffers LJ, Milikowski C, Molina EG, et al. (2002) Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 97: 2614-2618.
37. Hermeziu B, Messous D, Fabre M, Munteanu M, Baussan C, et al. (2010) Evaluation of FibroTest-ActiTest in children with chronic hepatitis C virus infection. Gastroenterol Clin Biol 34: 16-22.
38. El-Shabrawi MH, Mohsen NA, Sherif MM, El-Karaksy HM, Abou-Yosef H, et al. (2010) Noninvasive assessment of hepatic fibrosis and necroinflammatory activity in Egyptian children with chronic hepatitis C virus infection using FibroTest and ActiTest. Eur J Gastroenterol Hepatol 22: 946-951.
39. Friedman S, (2003) Liver fibrosis: from bench to bedside. J Hepatol 38: S38-53.
40. Gressner A, (1998) The cell biology of liver fibrogenesis- an imbalance of proliferation, growth arrest and apoptosis of myofibroblasts. Cell Tissue Res 292: 447-452.
41. Gressner A, Weiskirchen R, (2006) Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-beta as major players and therapeutic targets. J Cell Mol Med 10: 76-99.
42. Powell E, Edwards-Smith C, Hay J, Clouston A, Crawford D, et al. (2000) Host genetic factors influence disease progression in chronic hepatitis C. Hepatology 31: 828-833.
43. Goto T, Mikami K, Miura K, Ohshima S, Yoneyama K, et al. (2004) Mechanical stretch induces matrix metalloproteinase 1 production in human hepatic stellate cells. Pathophysiology 11: 153-158.
44. Friedman S, (2008) Mechanisms of hepatic fibrogenesis. Gastroenterology 134: 1655-1669.
45. Miyoshi H, Moriya K, Tsutsumi T, Shinzawa S, Fujie H, et al. (2011) Pathogenesis of lipid metabolism disorder in hepatitis C: Polyunsaturated fatty acids counteract lipid alterations induced by the core protein. J Hepatol 54: 432-438.
46. Okuda M, Li K, Beard MR, Showalter LA, Scholle F, et al. (2002) Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology 122: 366-375.
47. Taniguchi H, Kato N, Otsuka M, Goto T, Yoshida H, et al. (2004) Hepatitis C virus core protein upregulates transforming growth factor-beta 1 transcription. J Med Virol 72: 52-59.
48. Plebani M, Basso D, (2007) Non-invasive assessment of chronic liver and gastric diseases. 2007. Clin Chim Acta 381: 39-49.
49. Murphy FR, Issa R, Zhou X, Ratnarajah S, Nagase H, et al. (2002) Inhibition of apoptosis of activated hepatic stellate cells by tissue inhibitor of metalloproteinase-1 is mediated via effects on matrix metalloproteinase inhibition: implications for reversibility of liver fibrosis. J Biol Chem 277: 11069-11076.
50. Resino S, Bellón J, Asensio C, Micheloud D, Miralles P, et al. (2010) Can serum hyaluronic acid replace simple non-invasive indexes to predict liver fibrosis in HIV/Hepatitis C coinfected patients? BMC Infect Dis 10: 244.
51. Lebensztejn DM, Sobaniec-Lotowska ME, Kaczmarski M, Voelker M, Schuppan D, (2006) Matrix-derived serum markers in monitoring liver fibrosis in children with chronic hepatitis B treated with interferon alpha. World J Gastroenterol 12: 3338-3343.
52. Nobili V, Alisi A, Torre G, De Vito R, Pietrobattista A, et al. (2010) Hyaluronic acid predicts hepatic fibrosis in children with nonalcoholic fatty liver disease. Transl Res 156: 229-234.
53. Lebensztejn DM, Kaczmarski M, Sobaniec-Łotowska M, Bauer M, Voelker M, et al. (2004) Serum laminin-2 and hyaluronan predict severe liver fibrosis in children with chronic hepatitis B. Hepatology 39: 868-869.
54. Elmetwally IM, Elmahalaway AM, Abuhashem SH, ahmed AM, (2009) Determination of serum fibrosis index in patients with chronic hepatitis and its relationship to histological activity index. Saudi Med J 30: 638-646.
55. Saltik-Temizel IN, Koçak N, Ozen H, Demir H, (2004) Serum hyaluronic acid concentrations in children with cirrhosis. Indian J Gastroenterol 23: 129-130.
56. Hartley JL, Brown RM, Tybulewicz A, Hayes P, Wilson DC, et al. (2006) Hyaluronic acid predicts hepatic fibrosis in children with hepatic disease. J Pediatr Gastroenterol Nutr 43: 217-221.
57. Poynard T, Halfon P, Castera L, Charlotte F, Le Bail B, et al. (2007) Variability of the area under the receiver operating characteristic curves in the diagnostic evaluation of liver fibrosis markers: impact of biopsy length and fragmentation. Aliment Pharmacol Ther 25: 733-739.
58. Nelson DR, Gonzalez-Peralta RP, Qian K, Xu Y, Marousis CG, et al. (1997) Transforming growth factor-beta 1 in chronic hepatitis C. J Viral Hepat 4: 29-35.
59. Soliman GM, Mohammed KA, Taha A, barrack AA, (2010) The role of plasma transforming growth factor beta-1 in the development of fibrosis in patient with HCV related steatohepatitis. J Egypt Soc Parasitol 40: 759-772.
60. Rallón NI, Barreiro P, Soriano V, García-Samaniego J, López M, Benito JM, (2011) Elevated TGF-β1 levels might protect HCV/ HIV-coinfected patients from liver fibrosis. Eur J Clin Invest 41: 70-76.